School of Paediatrics and Reproductive Health, Robinson Institute, University of Adelaide, Adelaide, South Australia, Australia.
Am J Pathol. 2011 Dec;179(6):3075-85. doi: 10.1016/j.ajpath.2011.08.021. Epub 2011 Oct 12.
A disintegrin and metalloprotease with thrombospondin motifs protein 1 (ADAMTS1) is a protease commonly up-regulated in metastatic carcinoma. Its overexpression in cancer cells promotes experimental metastasis, but whether ADAMTS1 is essential for metastatic progression is unknown. To address this question, we investigated mammary cancer progression and spontaneous metastasis in the MMTV-PyMT mouse mammary tumor model in Adamts1 knockout mice. Adamts1(-/-)/PyMT mice displayed significantly reduced mammary tumor and lung metastatic tumor burden and increased survival, compared with their wild-type and heterozygous littermates. Histological examination revealed an increased proportion of tumors with ductal carcinoma in situ and a lower proportion of high-grade invasive tumors in Adamts1(-/-)/PyMT mice, compared with Adamts1(+/+)/PyMT mice. Increased apoptosis with unaltered proliferation and vascular density in the Adamts1(-/-)/PyMT tumors suggested that reduced cell survival accounts for the lower tumor burden in ADAMTS1-deficient mice. Furthermore, Adamts1(-/-) tumor stroma had significantly lesser amounts of proteolytically cleaved versican and increased numbers of CD45(+) leukocytes. Characterization of immune cell gene expression indicated that cytotoxic cell activation was increased in Adamts1(-/-) tumors, compared with Adamts1(+/+) tumors. This finding is supported by significantly elevated IL-12(+) cell numbers in Adamts1(-/-) tumors. Thus, in vivo ADAMTS1 may promote mammary tumor growth and progression to metastasis in the PyMT model and is a potential therapeutic target to prevent metastatic breast cancer.
整合素金属蛋白酶与血小板反应蛋白 1(ADAMTS1)是一种在转移性癌中普遍上调的蛋白酶。其在癌细胞中的过度表达促进了实验性转移,但 ADAMTS1 是否对转移进展至关重要尚不清楚。为了解决这个问题,我们在 MMTV-PyMT 小鼠乳腺肿瘤模型中研究了 Adamts1 敲除小鼠的乳腺肿瘤进展和自发性转移。与野生型和杂合型同窝仔相比,Adamts1(-/-)/PyMT 小鼠的乳腺肿瘤和肺转移瘤负担明显减少,存活率增加。组织学检查显示,与 Adamts1(+/+)/PyMT 小鼠相比,Adamts1(-/-)/PyMT 小鼠中具有导管原位癌的肿瘤比例增加,而高级别浸润性肿瘤的比例降低。Adamts1(-/-)/PyMT 肿瘤中的细胞凋亡增加,而增殖和血管密度不变,这表明 ADAMTS1 缺失小鼠中肿瘤负担降低是由于细胞存活减少所致。此外,Adamts1(-/-)肿瘤基质中经蛋白水解切割的 versican 明显减少,而 CD45(+)白细胞数量增加。免疫细胞基因表达的特征表明,与 Adamts1(+/+)肿瘤相比,Adamts1(-/-)肿瘤中细胞毒性细胞的激活增加。这一发现得到了 Adamts1(-/-)肿瘤中 IL-12(+)细胞数量显著增加的支持。因此,ADAMTS1 在体内可能促进 PyMT 模型中的乳腺肿瘤生长和转移进展,是预防转移性乳腺癌的潜在治疗靶点。